Natixis Advisors LLC Buys 4,390 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Natixis Advisors LLC grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 10.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,713 shares of the medical research company’s stock after buying an additional 4,390 shares during the quarter. Natixis Advisors LLC owned 0.16% of Bio-Rad Laboratories worth $15,017,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Venturi Wealth Management LLC increased its position in Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 87 shares during the last quarter. Picton Mahoney Asset Management increased its position in shares of Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 35 shares during the last quarter. Asset Planning Inc purchased a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at about $33,000. UMB Bank n.a. lifted its stake in shares of Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after purchasing an additional 32 shares during the period. Finally, Cape Investment Advisory Inc. purchased a new position in shares of Bio-Rad Laboratories in the fourth quarter worth approximately $38,000. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Up 1.2 %

Shares of BIO stock opened at $260.16 on Wednesday. Bio-Rad Laboratories, Inc. has a one year low of $244.00 and a one year high of $387.99. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. The company has a market capitalization of $7.29 billion, a price-to-earnings ratio of -4.00 and a beta of 0.98. The company’s fifty day moving average price is $308.56 and its 200-day moving average price is $326.91.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Wells Fargo & Company decreased their price target on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Bio-Rad Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $395.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.